Sprint Bioscience AB (publ) (FRA:5JA1)
Germany
· Delayed Price · Currency is EUR 0.1290
+0.0060 (4.88%)
At close: Dec 4, 2025
Sprint Bioscience AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 49.53 | 65.64 | 50.49 | 0.08 | 35.11 | 16.89 | Upgrade
|
| Other Revenue | 0.5 | 0.5 | 1.2 | - | -0.09 | 2.31 | Upgrade
|
| Revenue | 50.03 | 66.14 | 51.69 | 0.08 | 35.03 | 19.2 | Upgrade
|
| Revenue Growth (YoY) | -18.59% | 27.97% | 62171.08% | -99.76% | 82.48% | -43.23% | Upgrade
|
| Cost of Revenue | 18.88 | 28.34 | 8.7 | 12.93 | 10.44 | 10.46 | Upgrade
|
| Gross Profit | 31.15 | 37.8 | 42.99 | -12.85 | 24.59 | 8.74 | Upgrade
|
| Selling, General & Admin | 55.91 | 56.28 | 45.07 | 47.44 | 49.47 | 45.71 | Upgrade
|
| Other Operating Expenses | -1.36 | -0.67 | -1.21 | -0.29 | - | - | Upgrade
|
| Operating Expenses | 55.39 | 56.57 | 44.31 | 47.77 | 50.06 | 46.41 | Upgrade
|
| Operating Income | -24.24 | -18.77 | -1.32 | -60.62 | -25.47 | -37.68 | Upgrade
|
| Interest Expense | -1.35 | -0.04 | - | -0 | -0.27 | -3.44 | Upgrade
|
| Interest & Investment Income | 0.84 | 1.43 | 0.79 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.9 | -0.9 | 0.09 | 0.45 | 0.69 | -1.08 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | -0 | -0.04 | -0.6 | Upgrade
|
| EBT Excluding Unusual Items | -25.65 | -18.28 | -0.44 | -60.17 | -25.08 | -42.79 | Upgrade
|
| Pretax Income | -25.65 | -18.28 | -0.44 | -60.17 | -25.08 | -42.79 | Upgrade
|
| Net Income | -25.65 | -18.28 | -0.44 | -60.17 | -25.08 | -42.79 | Upgrade
|
| Net Income to Common | -25.65 | -18.28 | -0.44 | -60.17 | -25.08 | -42.79 | Upgrade
|
| Shares Outstanding (Basic) | 84 | 70 | 70 | 42 | 29 | 17 | Upgrade
|
| Shares Outstanding (Diluted) | 84 | 70 | 70 | 42 | 29 | 17 | Upgrade
|
| Shares Change (YoY) | 19.80% | 0.01% | 65.98% | 45.85% | 71.85% | 49.55% | Upgrade
|
| EPS (Basic) | -0.31 | -0.26 | -0.01 | -1.43 | -0.87 | -2.55 | Upgrade
|
| EPS (Diluted) | -0.31 | -0.26 | -0.01 | -1.43 | -0.87 | -2.55 | Upgrade
|
| Free Cash Flow | -39 | -24.65 | 20.42 | -59.05 | -42.82 | -32.22 | Upgrade
|
| Free Cash Flow Per Share | -0.47 | -0.35 | 0.29 | -1.40 | -1.49 | -1.92 | Upgrade
|
| Gross Margin | 62.27% | 57.16% | 83.17% | - | 70.21% | 45.51% | Upgrade
|
| Operating Margin | -48.45% | -28.37% | -2.56% | -73031.32% | -72.70% | -196.28% | Upgrade
|
| Profit Margin | -51.27% | -27.63% | -0.85% | -72493.98% | -71.61% | -222.93% | Upgrade
|
| Free Cash Flow Margin | -77.96% | -37.27% | 39.50% | -71149.40% | -122.26% | -167.87% | Upgrade
|
| EBITDA | -23.4 | -17.81 | -0.88 | -60 | -24.88 | -36.98 | Upgrade
|
| EBITDA Margin | -46.78% | -26.93% | -1.70% | - | -71.02% | -192.64% | Upgrade
|
| D&A For EBITDA | 0.84 | 0.96 | 0.45 | 0.62 | 0.59 | 0.7 | Upgrade
|
| EBIT | -24.24 | -18.77 | -1.32 | -60.62 | -25.47 | -37.68 | Upgrade
|
| EBIT Margin | -48.45% | -28.37% | -2.56% | - | -72.70% | -196.28% | Upgrade
|
| Revenue as Reported | 51.06 | 67.44 | 54.32 | 0.45 | 35.07 | 19.61 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.